Sarepta Therapeutics' stock experienced a significant after-hours plunge of 5.06% following the release of its fourth-quarter financial results.

The biopharmaceutical company reported a quarterly adjusted loss of $3.58 per share, which missed analyst estimates of a $1.31 loss by a wide margin of 172.45%. This represents a dramatic 288.42% decrease compared to earnings of $1.90 per share in the same period last year. While quarterly sales of $442.934 million exceeded consensus estimates by 13.02%, they still reflected a concerning 32.73% year-over-year decline.

Further details from the earnings report revealed a 33% drop in total revenues to $442.9 million for the quarter, with the company posting substantial GAAP and non-GAAP net losses. The financial performance was accompanied by regulatory updates including an FDA-approved label change for Elevidys that added a boxed warning for serious liver injury.